羧肽酶G2的研究进展  

Research advance in carboxypeptidase G2

作　　者：龙成[1] 易铁男[1] 孙志华[1] 王越华[1] 肖天林[1] 孙秋实[1] 

机构地区：[1]湖北文理学院襄阳市中心医院肿瘤科,襄阳441021

出　　处：《实用药物与临床》2016年第5期636-638,共3页Practical Pharmacy and Clinical Remedies

摘　　要：羧肽酶G2是一种通过将甲氨蝶呤转化为非毒性代谢物进而降低血清甲氨蝶呤浓度的细菌酶。将羧肽酶G2应用于经标准解救治疗后的患者,患者血清MTX浓度快速下降。羧肽酶G2耐受性较好,毒副反应多为1、2级毒副反应,无需处置,是一种独特的甲氨蝶呤解毒剂,但其在临床中的应用仍有一定的局限性与争议。Carboxypeptidases G2 is a bacterial enzyme that results in a decrease in plasma MTX concentrations by hydrolysis of MTX to inactive metabolites. Patients treated with carboxypeptidases G2 in addition to standard supportive care has a remarkable and rapid reduction in serum methotrexate level. Carboxypeptidases G2 is well tolerated,the most common adverse effects being typically grade 1 or 2 in severity and resolved without any intervention.However the clinical application of carboxypeptidases G2 still has some limitations and controversy.

关 键 词：羧肽酶G2 甲氨蝶呤 肾损害 

分 类 号：R977.3[医药卫生—药品]